Drugs cause approximately 20% of community- and hospital-acquired episodes of acute kidney failure (1–3). Among older adults, the incidence of drug-induced nephrotoxicity may be as high as 66% (4). Drug-induced nephrotoxicity may account for 20% of acute kidney injury (AKI), including both acute and chronic kidney disease. Prospective cohort studies of AKI have documented the frequency of drug-induced nephrotoxicity to be approximately 14%−26% in intensive care unit cohorts (5–7).
A growing body of literature highlights the potential for drugs to induce not only AKI but also glomerular diseases, termed drug-induced glomerular diseases. Patients with glomerular involvement generally present with one of five clinical syndromes: recurrent macroscopic hematuria, microscopic hematuria associated with proteinuria, heavy proteinuria or nephritic/nephrotic syndrome, rapidly progressive glomerulonephritis (RPGN), or chronic glomerulonephritis (GN). Strict monitoring of kidney function, urine and blood abnormalities, and blood pressure must be performed in patients undergoing therapy with potentially toxic drugs. It is critical to recognize these conditions early, because in many patients, there is improvement after removing the offending medication (8). In certain scenarios, removal of the offending agent plus an immunosuppressive strategy has been employed. However, the effectiveness of immunosuppressive therapy in this context has not been determined. From a diagnostic and therapeutic standpoint, it is sometimes difficult to ascribe a drug as being directly causative versus unmasking a preexisiting syndrome.
Drug-induced glomerular diseases can also be classified into two categories: direct cellular toxicity and immune-mediated injury (Table 1).
Kaufman J, et al.. Community-acquired acute renal failure. Am J Kidney Dis 1991; 17:191–198. doi: 10.1016/s0272-6386(12)81128-0
Nash K, et al.. Hospital-acquired renal insufficiency. Am J Kidney Dis 2002; 39:930–936. doi: 10.1053/ajkd.2002.32766
Bellomo R. The epidemiology of acute renal failure: 1975 versus 2005. Curr Opin Crit Care 2006; 12:557–560. doi: 10.1097/01.ccx.0000247443.86628.68
Kohli HS, et al.. Treatment-related acute renal failure in the elderly: a hospital-based prospective study. Nephrol Dial Transplant 2000; 15:212–217. doi: 10.1093/ndt/15.2.212
Mehta RL, et al.. Spectrum of acute renal failure in the intensive care unit: The PICARD experience. Kidney Int 2004; 66:1613–1621. doi: 10.1111/j.1523-1755.2004.00927.x
Uchino S, et al.. Acute renal failure in critically ill patients: A multinational, multicenter study. JAMA 2005; 294:813–818. doi: 10.1001/jama.294.7.813
Hoste EAJ, et al.. Epidemiology of acute kidney injury in critically ill patients: The multinational AKI-EPI study. Intensive Care Med 2015; 41:1411–1423. doi: 10.1007/s00134-015-3934-7
Radhakrishnan J, Perazella MA. Drug-induced glomerular disease: Attention required! Clin J Am Soc Nephrol 2015; 10:1287–1290. doi: 10.2215/CJN.01010115
Markowitz GS, et al.. Drug-induced glomerular disease: Direct cellular injury. Clin J Am Soc Nephrol 2015; 7:1292–1300. doi: 10.2215/CJN.00860115
Izzedine H, Perazella MA. Thrombotic microangiopathy, cancer, and cancer drugs. Am J Kidney Dis 2015; 66:857−868. doi: 10.1053/j.ajkd.2015.02.340
Palma LMP, et al.. Complement in secondary thrombotic microangiopathy. Kidney Int Rep 2021; 6:11−23. doi: 10.1016/j.ekir.2020.10.009
Nasr SH, D’Agati VD. Nodular glomerulosclerosis in the nondiabetic smoker. J Am Soc Nephrol 2007; 18:2032–2036. doi: 10.1681/ASN.2006121328
Markowitz GS, et al.. Idiopathic nodular glomerulosclerosis is a distinct clinicopathologic entity linked to hypertension and smoking. Hum Pathol 2002; 33:826–835. doi: 10.1053/hupa.2002.126189
Kim JS, et al.. Concurrent drug-induced linear immunoglobulin A dermatosis and immunoglobulin A nephropathy. Ann Dermatol 2015; 27:315−318. doi: 10.5021/ad.2015.27.3.315
Hogan JJ, et al.. Drug-induced glomerular disease: Immune-mediated injury. Clin J Am Soc Nephrol 2015; 10:1300–1310. doi: 10.2215/CJN.01910215
Xiao X, Chang C. Diagnosis and classification of drug-induced autoimmunity (DIA). J Autoimmun 2014; 48–49:66–72. doi: 10.1016/j.jaut.2014.01.005
Izzedine H, et al.. Drug-induced glomerulopathies. Expert Opin Drug Saf 2006; 5:95–106. doi: 10.1517/147403184.108.40.206
Kaneko T, et al.. A case of gefitinib-associated membranous nephropathy in treatment for pulmonary adenocarcinoma. CEN Case Rep 2015; 4:31−37. doi: 10.1007/s13730-014-0135-0
Lin JS, et al.. Immune checkpoint inhibitor associated reactivation of primary membranous nephropathy responsive to rituximab. J Immunother Cancer 2020; 8:e001287. doi: 10.1136/jitc-2020-001287
Radford MG Jr., et al.. Reversible membranous nephropathy associated with the use of nonsteroidal anti-inflammatory drugs. JAMA 1996; 276:466–469. doi: 10.1001/jama.1996.03540060042033